Blood count and fasting blood glucose level in the assessment of prognosis and survival in advanced cervical cancer

Abstract

OBJECTIVE:The objective of this study was to verify whether the parameters of the blood count and the fasting glucose level before treatment are related to prognosis and survival in cervical cancer (IIB-IVB staging). METHODS: Patients with cervical cancer (stages IIB-IVB) were evaluated (n=80). Age, parity, staging, histological grade, histological type, hemoglobin, red blood cells, hematocrit, neutrophil, lymphocyte and platelet counts, red blood cell distribution width, neutrophil-lymphocyte ratio, plateletlymphocyte ratio, fasting glucose levels, overall survival, and disease-free survival were evaluated. The results of laboratory parameters were compared using the Mann-Whitney U test. Receiver operating characteristic curve was used to obtain the area under the curve and determine the best cutoff values for each parameter. Survival was verified by using the Kaplan-Meier method, followed by the log-rank test. The level of significance was ≤0.05. RESULTS: Regarding staging, lower hemoglobin values (p=0.0013), red blood cells (p=0.009), hematocrit (p=0.0016), higher leukocytes (p=0.0432), neutrophils (p=0.0176), platelets (p=0.0140), red blood cell distribution width (RDW) (p=0.0073), neutrophil-lymphocyte ratio (p=0.0039), plateletlymphocyte ratio (p=0.0006), and fasting glucose level (p=0.0278) were found in IIIA-IVB compared with IIB staging. Shorter disease-free survival was associated with hemoglobin ≤12.3 g/dl (p=0.0491), hematocrit ≤38.5% (p=0.05), neutrophil-lymphocyte ratio >2.9 (p=0.0478), and plateletlymphocyte ratio >184.9 (p=0.0207). Shorter overall survival was associated with hemoglobin ≤12.3 g/dl (p=0.0131), hematocrit ≤38.5% (p=0.0376), neutrophil-lymphocyte ratio >2.9 (p=0.0258), and platelet-lymphocyte ratio >184.9 (p=0.0038). CONCLUSION: The analysis of these low-cost and easily accessible parameters could be a way to monitor patients in order to predict treatment failures and act as early as possible.

A Novel Nutrition-Related Prognostic Biomarker for Predicting Survival in Patients with Colorectal Cancer

“…In our study, we also evaluated other pertinent markers, including ALB, AGR, total protein, Hb, and BMI, which have previously been reported as indicative of survival in CRC. Moreover, we introduced red blood cell count (RBC) as an additional marker, despite limited research evidence, which has demonstrated its potential for predicting the long-term prognosis of hepatocellular carcinoma and cervical cancer [13,30]. However, its speci c role in prognostic assessment for CRC patients remains an area warranting further investigation.…”

Promising applications of red cell distribution width in diagnosis and prognosis of diseases with or without disordered iron metabolism

“…The ratio of Hb to RDW (HRR) is a convenient prognostic marker for small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and pulmonary large cell neuroendocrine carcinoma (PLCNEC) (Zhao et al, 2022). The combination of RDW, weight loss, and the metastatic lymph nodes were risk factors for the poor survival of patients with advanced oral cancer independent of other clinical and pathological characteristics (Trevisani et al, 2021) platelet-lymphocyte ratio > 184.9, and higher fasting glucose level, (Mota et al, 2022) the increased RDW-to-albumin ratio is independently associated with increased all-cause mortality in cancer patients (Lu et al, 2022).…”

“…The combination of RDW, weight loss, and the metastatic lymph nodes were risk factors for the poor survival of patients with advanced oral cancer independent of other clinical and pathological characteristics (Trevisani et al, 2021). Although shorter overall survival and disease‐free survival are associated with Hb ≤ 12.3 g/dL, hematocrit ≤ 38.5%, neutrophil–lymphocyte ratio > 2.9, platelet–lymphocyte ratio > 184.9, and higher fasting glucose level, (Mota et al, 2022) the increased RDW‐to‐albumin ratio is independently associated with increased all‐cause mortality in cancer patients (Lu et al, 2022).…”